Life Science Solutions

Every formulation decision made early in development carries downstream implications for stability, manufacturing, scalability, and analytical strategy. As therapies become more complex and development timelines compress, getting formulation right from the start has never mattered more.

In this episode of Life Science Solutions, host Chris Adkins sits down with Kymanox experts Ryan Doxey, VP of Technical Services, and Matt Owen, PhD Associate Director of CMC and Pharmaceutical Sciences. Together, they introduce the newly announced Kymanox Formulation Lab and discuss why having dedicated wet lab space is essential for true IND-enabling formulation development.

While Contract Development and Manufacturing Organizations (CDMOs) are built for throughput and execution, they are typically not staffed or equipped to troubleshoot complex scientific issues. This episode explores how applying a "science driving success" approach early on bridges that gap and ensures that your clinical manufacturing timelines stay on track.

Topics Include:
  • The CDMO Bottleneck: Why contract manufacturers lack the agility to spend adequate time developing formulations, and how unsolved early issues cause costly delays in Phase 1 and Phase 2 clinical manufacturing.
  • Quality by Design (QbD): Why developing a product merely to meet a Certificate of Analysis (CFA) is insufficient, and the importance of truly understanding your design space to inherently ensure a quality product.
  • Real-World Case Studies: How unknown peaks during forced degradation/leachable studies can derail timelines, and why understanding complex interactions like heat-catalyzed oxidation is crucial before scaling up.
  • Advanced Characterization: Why CDMOs often skip critical tests like permeation and mucus adhesion studies, and how using tools like nasal cast models ensures an intranasal product has adequate residence time and efficacy.
  • Future Trends: The push for biologics and the resurgence of spray-dried formulations to improve global storage conditions, especially as standard injection vehicles struggle to handle the viscosity of high-concentration antibodies.
Taking a thoughtful, science-driven approach to early formulation can help reduce risk and avoid costly development delays.

🎧 Subscribe to Life Science Solutions wherever you get your podcasts, and share this episode with your formulation, quality, and device engineering teams!

What is Life Science Solutions?

Presented by Kymanox, Life Science Solutions is dedicated to accelerating understanding and advancing expertise in the life sciences industry. Focused on bringing industry insights to light, our podcast offers a platform where regulatory, scientific, and engineering experts share practical knowledge on overcoming the challenges of product development and commercialization. Episodes equip listeners with the latest on regulatory updates, market trends, cutting-edge technology, and more. Join us as we explore the journey of modern medicines, ensuring every product reaches its full potential in safety, quality, and accessibility.